Ketogenic Interventions for PKD
A comprehensive overview of the research on ketogenic diet, ketone supplements, and metabolic interventions for Polycystic Kidney Disease.
Scientific Rationale
PKD cysts rely heavily on glucose for growth through a metabolic shift similar to the Warburg effect in cancer cells. A ketogenic state may counteract cyst growth through multiple mechanisms:
- Beta-hydroxybutyrate (BHB) — the primary ketone body — may directly inhibit cyst cell proliferation through signaling pathways independent of its role as fuel
- AMPK activation — ketosis activates AMP-activated protein kinase, which inhibits mTOR signaling (a key driver of cyst growth)
- Glucose deprivation — reducing glucose availability may "starve" glucose-dependent cyst cells
- CFTR inhibition — AMPK activation inhibits chloride secretion through CFTR channels, reducing cyst fluid accumulation
Initial preclinical work by Thomas Weimbs' lab at UCSB demonstrated that ketosis slowed cyst growth in animal models, leading to the first human trials.
Active Clinical Trials
There are currently four clinical trials investigating ketogenic interventions for ADPKD — the most activity this field has ever seen.
Juntendo University
KetoCitra + Ren-Nu · >50 patients · Tokyo
First trial to shrink kidneys in ADPKD
Ohio State / Jeff Volek
Keto diet alone · 20 patients · 52 weeks
DoD-funded · Continuous ketone monitoring
Cleveland Clinic
KetoCitra + Ren-Nu · 20 patients · 3 months
Independent academic validation
KETO-CKD (Denmark)
Exogenous ketones · 14 patients · Crossover RCT
Only double-blinded ketone trial in PKD
Juntendo University Trial (2025–2026)
First intervention to demonstrate actual kidney volume decrease in ADPKD
Led by Dr. Shigeo Horie at Juntendo University (Tokyo), this is the first clinical trial in Asia investigating ketogenic metabolic therapy for ADPKD. Results have been presented at ASN 2025 and WCN 2026.
3-Month Results (ASN 2025)
TKV: -5.01% (intervention) vs +8.03% (control) — statistically significant
eGFR: +0.59 (intervention) vs -1.57 mL/min (control)
100% adherence — zero participants discontinued
12-Month Results (WCN 2026)
TKV significantly decreased (p=0.026) in 7 completers — kidneys actually shrank over 12 months
Liver volume significantly decreased at both 3 and 12 months
Strong dose-response: ketone levels correlated with kidney shrinkage (ρ = -0.86, p=0.012)
eGFR stabilized vs historical pre-trial decline of -5.6 mL/min/year
For comparison, tolvaptan (TEMPO 3:4) only slowed kidney growth from +5.51%/year to +2.80%/year — kidneys still grow. This is the first intervention where kidneys actually shrank.
Enrollment completed with >50 participants plus a control group. Final results expected in approximately one year. Read full analysis →
Ohio State / Jeff Volek Trial (2024–2026)
First year-long keto diet trial in U.S. with continuous ketone monitoring — DoD funded
Status
Recruiting
Patients
20
Duration
52 weeks
Completion
Dec 2026
Led by Jeff Volek, PhD — one of the world's foremost ketogenic diet researchers — at Ohio State University. Funded by the U.S. Department of Defense. This is the longest-duration ketogenic diet trial for ADPKD, testing diet alone (no KetoCitra) in high-risk patients (Mayo Class 1C-1E).
Patients follow a well-formulated ketogenic diet (<50g carbs/day) for a full year with continuous glucose and ketone monitoring, DEXA scans, and MRI-based kidney volume measurement at baseline, 6 months, and 12 months.
NCT06325644. Primary completion estimated December 2026. Read full analysis →
KETO-ADPKD Trial
Status
Completed
Patients
66
Duration
3 months
Published
Nov 2023
The KETO-ADPKD trial (NCT04680780) was the first randomized controlled trial of ketogenic diet in ADPKD patients, led by Roman-Ulrich Müller at the University of Cologne in collaboration with Thomas Weimbs. Published in Cell Reports Medicine (DOI).
Design
66 ADPKD patients were randomized to one of three arms: ketogenic diet (KD), water fasting (WF, 3 days/month), or control (standard diet) for 3 months.
Key Results
Feasibility: 95% of participants found the ketogenic diet feasible; significant ketogenesis was achieved
eGFR improvement: KD group showed +5.51% (creatinine-based) and +13.9% (cystatin-C-based) eGFR improvement while controls declined
Liver volume: Significant reduction in the KD group (-4.73%) vs. control (+2.04%)
Kidney volume: Trend in right direction (KD -0.55% vs. control +0.79%) but NOT statistically significant — likely underpowered and too short
Body composition: -7.2% body weight, -20.5% body fat in KD group
Safety: Only mild, transient "keto-flu" symptoms reported
Limitations
- - Short duration (3 months) — insufficient to detect kidney volume changes
- - Small sample size (66 patients) — underpowered for primary endpoint
- - Open-label design — participants knew their diet assignment
- - eGFR improvements may reflect hemodynamic changes, not structural benefit
RESET-PKD Pilot
A precursor pilot study with 10 ADPKD patients who underwent either a 14-day ketogenic diet or 3-day water fast. Established feasibility and safety.
- Significant liver volume reduction (-7.7%)
- Kidney volume change not significant in this short period
- Confirmed both interventions were safe and feasible in ADPKD patients
KetoCitra & Ketone Supplements
What is KetoCitra?
KetoCitra is classified as a "medical food" (not a drug or supplement) produced by Santa Barbara Nutrients, Inc., co-founded by Thomas Weimbs. It requires medical supervision and contains:
- BHB (beta-hydroxybutyrate) — to promote therapeutic ketosis
- Citrate — to prevent microcrystal formation that may trigger new cysts
- Electrolytes (K, Mg, Ca) — alkaline base load, sodium-free
Ren-Nu Program (Real-World Data, 2026)
Patients
103
Duration
3 months
Program
KetoCitra + keto diet + dietitian
Control group
None
Results:
- eGFR increased 6.3% (P<0.001)
- BMI improved
- Pain reduced, fewer anti-hypertensives needed
Key Preclinical Evidence
BHB alone recapitulates ketogenic therapy
Torres et al. — iScience, 2024 · DOI
Both D-BHB and L-BHB stereoisomers reduced cyst growth in PKD animal models, implying a signaling mechanism rather than purely metabolic effect.
BHB + Citrate synergistic effect
Torres et al. — Am J Physiol Renal Physiol, 2024 · DOI
Combination of BHB and citrate at lower doses outperformed either compound alone at higher doses in a rat PKD model, suggesting synergistic benefit.
DIPAK Consortium observational data
Knol et al. — Nephrol Dial Transplant, 2024 · DOI
In 521 ADPKD patients, higher endogenous BHB levels predicted 0.33 mL/min/1.73m² better annual eGFR slope (P=0.008). Independent support from the Netherlands.
2026 Reviews & Practical Guidance
Systematic Review: All KDI Studies in ADPKD
Metabolism Open, March 2026 — Grammatikopoulou et al.
The first comprehensive systematic review synthesizing all human studies of ketogenic interventions in ADPKD. Found that KDIs are safe (no adverse lipid/BP changes), eGFR was stable or improved in all studies, and weight loss was consistent. Concluded that metabolic feasibility is well-supported but longer trials are needed for structural kidney outcomes.
Read full analysis →Nutritional Adequacy of Keto Diets for ADPKD
Journal of Nephrology, April 2026 — Croucher et al. (University of Sydney)
Developed ADPKD-specific ketogenic meal plans and demonstrated they can meet nutritional requirements with only minor supplementation (iodine, iron, zinc). Also created modified versions addressing kidney stone risk and hyperkalemia. A practical resource supporting clinical implementation of keto for PKD.
Read full analysis →Time-Restricted Eating
Patients
29
Duration
12 months
Institution
Univ. of Colorado
Published
2025
29 patients were randomized to an 8-hour eating window (time-restricted eating) vs. healthy eating for 12 months, led by Kristen Nowak.
Key finding: Adherence target was not met (60% vs. 75% goal). Both groups lost modest weight. The study concluded that weight and adiposity loss may matter more than eating timing per se.
All Published Studies
Clinical Trials
Juntendo University 12-Month Interim Results
Sustained kidney and liver volume reduction with ketogenic metabolic therapy
Juntendo University, Tokyo • Kidney International Reports
Juntendo University 3-Month Interim Results
5% kidney volume reduction in 90 days with KetoCitra and nutritional changes
Juntendo University, Tokyo • JASN Volume 35, October 2025 supplement
Cleveland Clinic KetoCitra Trial
Major academic center validates ketogenic nutrition approach for ADPKD
Cleveland Clinic, Ohio •
Ohio State Well-Formulated Ketogenic Diet Trial
52-week keto diet with continuous ketone monitoring and MRI imaging in high-risk ADPKD
Ohio State University Wexner Medical Center •
Observational & Post-Hoc Analyses
Ren-Nu Real-World Outcomes (103 Patients)
eGFR improvement, reduced pain, and fewer medications in real-world ADPKD program
Santa Barbara Nutrients, Inc. • Frontiers in Nutrition, Volume 12, 2025
Post-Hoc Analysis: KETO-ADPKD Significant TKV Decrease
Re-analysis confirms ketogenic diet significantly reduced kidney volume in compliant patients
University of Cologne / UCSB • Under review / Preprint
Sustained Ketosis Improves Kidney Function in Diabetic CKD
Post-hoc analysis shows dose-response between ketosis levels and eGFR improvement in type 2 diabetes
Virta Health / Indiana University / Ohio State University • Frontiers in Nutrition
Systematic Review: Ketogenic Dietary Interventions for ADPKD
First comprehensive synthesis of all human keto-ADPKD studies confirms metabolic feasibility, calls for longer trials
University of Thessaly, Greece • Metabolism Open
Long-Term Ketogenic Therapy Halts Cyst Progression — Case Series
Four ADPKD patients with truncating PKD1 mutations show TKV stabilization or reduction over 6 months to 4 years
UC Santa Barbara / Santa Barbara Nutrients • Frontiers in Nutrition
Nutritional Adequacy of Ketogenic Diets for ADPKD
Well-planned keto diets can meet ADPKD nutritional requirements with minimal supplementation
University of Sydney, Australia • Journal of Nephrology
Preclinical Research
Ketosis Ameliorates Renal Cyst Growth in PKD
First evidence that ketogenic interventions slow cyst growth in animal models
UC Santa Barbara • Cell Metabolism
Food Restriction Ameliorates PKD Development
First demonstration that dietary intervention can slow polycystic kidney disease
UC Santa Barbara • American Journal of Physiology - Renal Physiology
Microcrystals Worsen PKD, Citrate is Protective
Crystal deposits trigger new cyst formation; citrate supplementation prevents it
UC Santa Barbara • Journal of Clinical Investigation (JCI)
Key Researchers
Thomas Weimbs, PhD
UC Santa Barbara
Foundational ketosis-PKD research. BHB mechanisms. Pioneer of metabolic interventions for PKD.
Roman-Ulrich Mueller, MD
University of Cologne
Led KETO-ADPKD and RESET-PKD clinical trials. First RCTs of ketogenic diet in ADPKD.
Jeff Volek, PhD, RD
Ohio State University
Leading keto researcher. Running the DoD-funded 52-week ADPKD trial with continuous ketone monitoring.
Kristen Nowak, PhD
University of Colorado
Time-restricted eating trial. Dietary interventions and metabolic health in ADPKD.
Ron Gansevoort, MD, PhD
Univ. of Groningen (DIPAK Consortium)
Independent observational study linking endogenous BHB levels to better eGFR outcomes in 521 ADPKD patients.